Therefore, a strategy containing chemotherapeutic agent, TLR-4 agonist, and PD-1/PD-L1-targeting peptide would effectively enhance the anti-tumor immunity and inhibit the aggressive growth of OS. The gene discussed is CD274; the disease is neoplasm.